ACE-031

Ergogenic / Myostatin

May increase skeletal muscle mass via myostatin/activin pathway blockade

Reading this compound Reference only

Information below is educational. Dosing, mechanisms and status fields are compiled from the source list at the bottom of this page — always verify against a licensed clinician before use.

Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.

Mechanism & Use

Compound type: Fusion protein
Primary mechanism: Soluble ACVR2B ligand trap
Primary market use: Muscle wasting

Pharmacology

Molecular weight (Da): ~110,000
Oral bioavailability: N/A
Half-life: ~10-15 d
Route tags: Route-dependent / verify
Evidence level: Human/Clinical
Clinical status: Discontinued investigational
Value-for-money score: 4 / 10

Reported protocol signal

No popular protocol verified yet; keep as reference compound until protocol signal is added.

For orientation only. See disclaimer — always consult a licensed clinician before use.

Notes

Durability depends on retained lean tissue; safety concerns historically limited development

Sources

https://clinicaltrials.gov/